The tested compound was evaluated in an EGFR cell-free assay for tyrosine kinase activities. A quantitative activity result was reported. SCC25 cells received compound treatment for 72 hours, with DMSO-treated cells as the control. The reported cell viability value was 207.29 ± 11.6 nM. NCI-H1975 cells received compound treatment, and cell viability was assessed 72 h after drug treatments using DMSO control values. The reported result was 0.21 ± 0.09 µM. In an ErbB2 cell-free assay, the study compound yielded a tyrosine kinase activity result of 3.0±1.5 nmol/L. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Tyrosine Kinase Activities in a Cell-Free Assay
Cell-based study · EGFR [1]
The tested compound was evaluated in an EGFR cell-free assay for tyrosine kinase activities. A quantitative activity result was reported.
Literature-Reported Treatment Conditions
- Method
- cell-free assay
- Reported limits
- Not stated in the sentences used: dose, schedule, vehicle, control.
Methods and source locations
Compound reported in the paper: AST-1306
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Cell proliferation, tyrosine kinase, and Western blot assay (S7); Results > AST1306 selectively inhibits the tyrosine kinase activities of EGFR and ErbB2 in vitro (S46, S47); Table 1 (T1.h1, T1.r1)
tyrosine kinase activities: tyrosine kinase activities — Materials and Methods > Cell proliferation, tyrosine kinase, and Western blot assay (S7); Table 1 (T1.h1, T1.r1)
Compound treatment and cell viability in SCC25 cells
Cell-based study · SCC25 [2]
SCC25 cells received compound treatment for 72 hours, with DMSO-treated cells as the control. The reported cell viability value was 207.29 ± 11.6 nM.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100, 200, 400, 600, 800 and 1000 nM
- Exposure duration
- 72 hours
- Method
- in DMEM-0.5%
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: AST-1306; Compound label in the paper: Allitinib
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESULTS > Viability effect of cetuximab, afatinib and allitinib in hnscc cell lines (S13); MATERIALS AND METHODS > Pharmacological agents (S62, S63); MATERIALS AND METHODS > Cell viability (S64, S66, S68)
Cell viability: Cell viability; comparator: DMSO treated control cells — RESULTS > Viability effect of cetuximab, afatinib and allitinib in hnscc cell lines (S13); MATERIALS AND METHODS > Cell viability (S64)
Cell viability after drug treatment in NCI-H1975 cells
Cell-based study · NCI-H1975 [3]
NCI-H1975 cells received compound treatment, and cell viability was assessed 72 h after drug treatments using DMSO control values. The reported result was 0.21 ± 0.09 µM.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.2; 0.4; 0.6; 0.8; 1.0; 2.0; 5.0 μM
- Exposure duration
- 72 h after drug treatments
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: AST-1306; Compound label in the paper: Allitinib
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
4. Materials and Methods > 4.2. Pharmacological Agents (S61); 4. Materials and Methods > 4.3. Cytotoxicity, Growth Inhibition, and Proliferation Analyses (S64, S66, S68); Table 1 (T1.h1, T1.h2, T1.r1)
cell viability: cell viability; comparator: DMSO control values — 4. Materials and Methods > 4.3. Cytotoxicity, Growth Inhibition, and Proliferation Analyses (S64); Table 1 (T1.h1, T1.h2, T1.r1)
ErbB2 Activity in a Cell-Free Assay
Cell-based study · ErbB2 [1]
In an ErbB2 cell-free assay, the study compound yielded a tyrosine kinase activity result of 3.0±1.5 nmol/L.
Literature-Reported Treatment Conditions
- Method
- cell-free assay
- Reported limits
- Not stated in the sentences used: dose, schedule, vehicle, control.
Methods and source locations
Compound reported in the paper: AST-1306
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Cell proliferation, tyrosine kinase, and Western blot assay (S7); Results > AST1306 selectively inhibits the tyrosine kinase activities of EGFR and ErbB2 in vitro (S46, S47); Table 1 (T1.h1, T1.r2)
tyrosine kinase activities: tyrosine kinase activities — Materials and Methods > Cell proliferation, tyrosine kinase, and Western blot assay (S7); Table 1 (T1.h1, T1.r2)
